Load Demo Scenario
β Normal
Negative workup
π¦ SLE (Renal)
dsDNA+, low C3/C4, Sm+
π Drug-Induced Lupus
ANA+, anti-histone+
𦴠Rheumatoid Arthritis
High RF + anti-CCP
π§ SjΓΆgren's
SSA/SSB+, RF+
π₯ SSc Diffuse
Anti-Scl-70+
π₯ SSc Limited
Anti-centromere+
π MCTD
High anti-U1 RNP
πͺ PM/DM
Anti-Jo1+, high CK
π« GPA
PR3-ANCA+
π« MPA
MPO-ANCA+
π©Έ APS
aCL+, Ξ²2GPI+, LA+
β UCTD
ANA+ non-specific
Core Autoantibodies
Scleroderma & Myositis Antibodies
Rheumatoid Arthritis Markers
ANCA & Vasculitis
Antiphospholipid Antibodies (2023 ACR/EULAR)
Inflammation / Complement / Enzymes
Analysis Results
β οΈ Educational Tool: This interpreter is for educational purposes only. Classification criteria are designed for research and may not capture all patients. Always correlate with clinical findings and consult specialists. Not a substitute for professional medical judgment.
Classification Criteria Summary
π¦ SLE β 2019 ACR/EULAR Criteria
Entry: ANA β₯1:80. Threshold: β₯10 points + β₯1 clinical criterion.
| Domain | Criterion | Weight |
|---|---|---|
| Immunologic | Anti-dsDNA OR Anti-Sm | 6 |
| Complement | Low C3 OR C4 / Both low | 3 / 4 |
| aPL | aCL, Ξ²2GPI, or LA | 2 |
| Renal | Class III/IV LN | 10 |
𦴠RA β 2010 ACR/EULAR Criteria
Threshold: β₯6 points with β₯1 swollen joint.
| Serology | Score |
|---|---|
| Negative RF AND anti-CCP | 0 |
| Low-positive (β€3ΓULN) | 2 |
| High-positive (>3ΓULN) | 3 |
π§ SjΓΆgren's β 2016 ACR/EULAR Criteria
Threshold: β₯4 points. Note: Anti-SSB/La alone NOT sufficient.
| Criterion | Weight |
|---|---|
| Anti-SSA/Ro positive | 3 |
| Focal lymphocytic sialadenitis (FSβ₯1) | 3 |
| Ocular Staining Score β₯5 | 1 |
| Schirmer's β€5mm/5min | 1 |
π₯ SSc β 2013 ACR/EULAR Criteria
Sufficient: Skin thickening proximal to MCPs. Otherwise: β₯9 points.
| Criterion | Weight |
|---|---|
| SSc antibodies (Scl-70, centromere, RNA Pol III) | 3 |
| Raynaud's phenomenon | 3 |
| Fingertip pitting scars | 3 |
| Telangiectasia / Abnormal nailfold capillaries | 2 |
π©Έ APS β 2023 ACR/EULAR Criteria
Entry: β₯1 aPL+ within 3 years of event. Threshold: β₯3 points each clinical AND laboratory.
| Laboratory Domain | Score |
|---|---|
| Lupus anticoagulant (persistent) | 5 |
| High aCL IgG or anti-Ξ²2GPI IgG | 4-7 |
| Isolated IgM positivity | 1 |
β οΈ 2023 criteria emphasize IgG over IgM. Isolated IgM has minimal weight.
π« ANCA Vasculitis β 2022 ACR/EULAR Criteria
| GPA Criteria | Score |
|---|---|
| PR3-ANCA positive | +5 |
| MPO-ANCA positive | -1 |
| Eosinophils β₯1Γ10βΉ/L | -4 |
| Nasal/sinus involvement | +3 |
| Granulomatous inflammation | +2 |
πͺ IIM β 2017 ACR/EULAR Criteria
Probability-based. Thresholds: Possible β₯50%, Probable β₯55%, Definite β₯90%.
| Variable | Points |
|---|---|
| Anti-Jo1 positive | 3.9 |
| Elevated CK | 1.3 |
| Gottron's papules | 2.1 |
| Heliotrope rash | 3.1 |
Note: Only anti-Jo1 included in criteria. Other MSAs (Mi2, MDA5, TIF1Ξ³, SRP) improve classification.
Reference Values
Autoantibody Cutoffs
| Test | Positive | Clinical Note |
|---|---|---|
| ANA (IIF) | β₯1:80 | Entry for SLE; β₯1:160 more specific |
| Anti-dsDNA | >Lab ULN | SLE-specific; correlates with nephritis |
| Anti-Sm | Positive | Highly specific for SLE (99%) |
| Anti-SSA/Ro | Positive | SjΓΆgren's (3 pts), SLE, neonatal lupus |
| RF / Anti-CCP | >ULN; >3ΓULN=high | Anti-CCP more specific than RF |
Complement & Inflammation
| Test | Normal | Note |
|---|---|---|
| C3 | 90-180 mg/dL | Low in active SLE |
| C4 | 10-40 mg/dL | Low in SLE, cryoglobulinemia |
| ESR | 0-20 mm/h | Non-specific inflammation |
| CRP | <10 mg/L | May be normal in SLE flare |
| CK | 30-200 U/L | >5ΓULN suggests myositis |
ANA Pattern Associations
| Pattern | Common Associations |
|---|---|
| Homogeneous | SLE, drug-induced lupus |
| Speckled | SSA/SSBβSjΓΆgren's; RNP/SmβMCTD/SLE |
| Nucleolar | Diffuse SSc (Scl-70) |
| Centromere | Limited SSc (CREST) |
| Cytoplasmic | Anti-Jo1, anti-SRP, anti-mitochondrial |